{"id":321236,"date":"2026-10-21T16:19:15","date_gmt":"2026-10-21T10:49:15","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=321236"},"modified":"2026-10-21T16:19:15","modified_gmt":"2026-10-21T10:49:15","slug":"oncology-generics-branded-generics-and-biologics-platform-stocks-roadmap-trailhead-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/oncology-generics-branded-generics-and-biologics-platform-stocks-roadmap-trailhead-list\/","title":{"rendered":"3 Oncology Generics, Branded Generics and Biologics Platform Stocks With a Strong Future Roadmap: Natco Pharma, Emcure Pharmaceuticals and Shilpa Medicare"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Natco Pharma, Emcure Pharmaceuticals and Shilpa Medicare: ROE of 9.4% to 18.7% and FY22 to FY26 revenue CAGR of 7.5% to 21.0%. Prices as of 20 Oct 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three specialty generics and oncology stocks to watch are Natco Pharma, Emcure Pharmaceuticals and Shilpa Medicare. Their return on equity ranges from 9.4% to 18.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.5% to 21.0%. Emcure Pharmaceuticals has the highest return on equity at 18.7%, while Natco Pharma has the fastest revenue growth at 21.0% a year. Prices are based on the 20 October 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Specialty generics and oncology stocks let investors follow companies that make harder-to-copy medicines. Natco Pharma, Emcure Pharmaceuticals and Shilpa Medicare combine complex generics, branded generics in India and Europe, and an integrated oncology and biologics platform.<\/p>\n<p>This list covers three specialty generics and oncology stocks with complete current figures: Natco Pharma, Emcure Pharmaceuticals and Shilpa Medicare. Every figure comes from the latest reported financials and the 20 October 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=oncology-generics-branded-generics-and-biologics-platform-stocks-roadmap-trailhead-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-branded-generics-and-biologics-platform-stocks-roadmap-trailhead-list\/#What_Are_Specialty_Generics_and_Oncology_Stocks\" title=\"What Are Specialty Generics and Oncology Stocks?\">What Are Specialty Generics and Oncology Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-branded-generics-and-biologics-platform-stocks-roadmap-trailhead-list\/#Specialty_Generics_and_Oncology_Stocks_at_a_Glance\" title=\"Specialty Generics and Oncology Stocks at a Glance\">Specialty Generics and Oncology Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-branded-generics-and-biologics-platform-stocks-roadmap-trailhead-list\/#Why_Do_Specialty_Generics_and_Oncology_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Specialty Generics and Oncology Stocks Have a Strong Roadmap in India?\">Why Do Specialty Generics and Oncology Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-branded-generics-and-biologics-platform-stocks-roadmap-trailhead-list\/#Why_Natco_Pharma_Features_Among_These_Specialty_Generics_and_Oncology_Stocks\" title=\"Why Natco Pharma Features Among These Specialty Generics and Oncology Stocks\">Why Natco Pharma Features Among These Specialty Generics and Oncology Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-branded-generics-and-biologics-platform-stocks-roadmap-trailhead-list\/#Why_Emcure_Pharmaceuticals_Features_Among_These_Specialty_Generics_and_Oncology_Stocks\" title=\"Why Emcure Pharmaceuticals Features Among These Specialty Generics and Oncology Stocks\">Why Emcure Pharmaceuticals Features Among These Specialty Generics and Oncology Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-branded-generics-and-biologics-platform-stocks-roadmap-trailhead-list\/#Why_Shilpa_Medicare_Features_Among_These_Specialty_Generics_and_Oncology_Stocks\" title=\"Why Shilpa Medicare Features Among These Specialty Generics and Oncology Stocks\">Why Shilpa Medicare Features Among These Specialty Generics and Oncology Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-branded-generics-and-biologics-platform-stocks-roadmap-trailhead-list\/#Natco_Pharma_vs_Emcure_Pharmaceuticals_vs_Shilpa_Medicare_on_Key_Financials\" title=\"Natco Pharma vs Emcure Pharmaceuticals vs Shilpa Medicare on Key Financials\">Natco Pharma vs Emcure Pharmaceuticals vs Shilpa Medicare on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-branded-generics-and-biologics-platform-stocks-roadmap-trailhead-list\/#Key_Risks_to_Check_Before_Investing_in_Specialty_Generics_and_Oncology_Stocks\" title=\"Key Risks to Check Before Investing in Specialty Generics and Oncology Stocks\">Key Risks to Check Before Investing in Specialty Generics and Oncology Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-branded-generics-and-biologics-platform-stocks-roadmap-trailhead-list\/#Final_Thoughts_on_Specialty_Generics_and_Oncology_Stocks\" title=\"Final Thoughts on Specialty Generics and Oncology Stocks\">Final Thoughts on Specialty Generics and Oncology Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-branded-generics-and-biologics-platform-stocks-roadmap-trailhead-list\/#What_are_specialty_generics_and_oncology_stocks\" title=\"What are specialty generics and oncology stocks?\">What are specialty generics and oncology stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-branded-generics-and-biologics-platform-stocks-roadmap-trailhead-list\/#Which_specialty_generics_and_oncology_stocks_are_covered_in_this_list\" title=\"Which specialty generics and oncology stocks are covered in this list?\">Which specialty generics and oncology stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-branded-generics-and-biologics-platform-stocks-roadmap-trailhead-list\/#Why_do_specialty_generics_and_oncology_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do specialty generics and oncology stocks have a strong future roadmap in India?\">Why do specialty generics and oncology stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-branded-generics-and-biologics-platform-stocks-roadmap-trailhead-list\/#How_has_Natco_Pharma_performed_financially\" title=\"How has Natco Pharma performed financially?\">How has Natco Pharma performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-branded-generics-and-biologics-platform-stocks-roadmap-trailhead-list\/#How_has_Emcure_Pharmaceuticals_performed_financially\" title=\"How has Emcure Pharmaceuticals performed financially?\">How has Emcure Pharmaceuticals performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-branded-generics-and-biologics-platform-stocks-roadmap-trailhead-list\/#How_has_Shilpa_Medicare_performed_financially\" title=\"How has Shilpa Medicare performed financially?\">How has Shilpa Medicare performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-branded-generics-and-biologics-platform-stocks-roadmap-trailhead-list\/#What_risks_should_investors_check_before_buying_specialty_generics_and_oncology_stocks\" title=\"What risks should investors check before buying specialty generics and oncology stocks?\">What risks should investors check before buying specialty generics and oncology stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/oncology-generics-branded-generics-and-biologics-platform-stocks-roadmap-trailhead-list\/#Is_this_list_of_specialty_generics_and_oncology_stocks_investment_advice\" title=\"Is this list of specialty generics and oncology stocks investment advice?\">Is this list of specialty generics and oncology stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Specialty_Generics_and_Oncology_Stocks\"><\/span><strong>What Are Specialty Generics and Oncology Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Specialty generics and oncology stocks are listed pharmaceutical companies that focus on complex generics, cancer medicines and biologics, which need more scientific skill than ordinary tablets. Their earnings depend on approvals, launches and the pace of capacity use.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Specialty_Generics_and_Oncology_Stocks_at_a_Glance\"><\/span><strong>Specialty Generics and Oncology Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/natcopharm\/natco-pharma-ltd-share-price-today\">Natco Pharma<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">800.85<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15,708<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.08<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/emcure\/emcure-pharmaceuticals-ltd-share-price-today\">Emcure Pharmaceuticals<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,766.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">33,487<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">32.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.31<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/shilpamed\/shilpa-medicare-ltd-share-price-today\">Shilpa Medicare<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">876.2<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17,132<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">57.6<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.25<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Natco Pharma and Emcure Pharmaceuticals trade at a P\/E below the industry P\/E, while Shilpa Medicare trades above it, which reflects the growth the market already expects. Readers comparing specialty generics and oncology stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Specialty_Generics_and_Oncology_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Specialty Generics and Oncology Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Specialty generics and oncology stocks have a strong roadmap in India because cancer care and biologic medicines are growing categories where fewer producers can compete and prices hold up better.<\/p>\n<ul>\n<li><strong>Cancer care demand.<\/strong> More diagnosis and treatment lifts demand for oncology medicines.<\/li>\n<li><strong>Complex products.<\/strong> Hard-to-make generics face fewer competitors.<\/li>\n<li><strong>Branded reach.<\/strong> Marketing arms in India and Europe build repeat demand.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Natco_Pharma_Features_Among_These_Specialty_Generics_and_Oncology_Stocks\"><\/span><strong>Why Natco Pharma Features Among These Specialty Generics and Oncology Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the specialty generics and oncology stocks on this list, Natco Pharma is a Hyderabad-based pharmaceutical company focused on complex generics, oncology, and active ingredients, with a significant presence in the United States and other regulated markets.<\/p>\n<p>Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%.<\/p>\n<p>The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P\/E of 13.7, below the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> The company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.<\/p>\n<p><strong>What to watch:<\/strong> Check the timing of key product launches in the US and the contribution from new drug approvals.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Emcure_Pharmaceuticals_Features_Among_These_Specialty_Generics_and_Oncology_Stocks\"><\/span><strong>Why Emcure Pharmaceuticals Features Among These Specialty Generics and Oncology Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the complex generic shares on this list, Emcure Pharmaceuticals, based in Pune, sells branded generics in India through marketing arms such as Zuventus and Avet, and also serves Europe, Canada and other markets.<\/p>\n<p>The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P\/E of 32.9, below the industry P\/E of 36.0.<\/p>\n<p>Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore.<\/p>\n<p><strong>Roadmap:<\/strong> It is strengthening its domestic branded portfolio in women&#8217;s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.<\/p>\n<p><strong>What to watch:<\/strong> Look at the growth of the India branded business and the pace of new launches abroad.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Shilpa_Medicare_Features_Among_These_Specialty_Generics_and_Oncology_Stocks\"><\/span><strong>Why Shilpa Medicare Features Among These Specialty Generics and Oncology Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Shilpa Medicare, headquartered in Raichur, Karnataka, is a pharmaceutical company with active ingredients, formulations, biologics and contract development and manufacturing under one roof, with a focus on oncology.<\/p>\n<p>Revenue rose from Rs 1,160 crore in FY22 to Rs 1,549 crore in FY26, a compound annual growth rate of 7.5%. Net profit grew from Rs 60.6 crore in FY22 to Rs 243 crore in FY26, which works out to a compound annual growth rate of 41.6%.<\/p>\n<p>In the June 2026 quarter, revenue grew 43.0% year on year to Rs 469 crore, while net profit rose 115.1% to Rs 101 crore. The company has a return on equity of 9.4%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 17,132 crore. The stock trades at a P\/E of 57.6, above the industry P\/E of 36.0.<\/p>\n<p><strong>Roadmap:<\/strong> Its path forward combines a growing biologics and specialty injectables pipeline with contract manufacturing for global partners. Multiple business lines give it more than one route to scale as regulatory approvals arrive.<\/p>\n<p><strong>What to watch:<\/strong> Follow regulatory approvals and commercial launches, since these drive the timing of earnings.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Natco_Pharma_vs_Emcure_Pharmaceuticals_vs_Shilpa_Medicare_on_Key_Financials\"><\/span><strong>Natco Pharma vs Emcure Pharmaceuticals vs Shilpa Medicare on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three specialty generics and oncology stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Natco Pharma<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,044<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">4,376<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">21.0%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,372<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">31.4%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Emcure Pharmaceuticals<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,919<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9,335<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.1%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">941<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">10.1%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Shilpa Medicare<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,160<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,549<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">7.5%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">243<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.7%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Emcure Pharmaceuticals posts the highest return on equity in this group at 18.7%. Emcure Pharmaceuticals has the largest FY26 revenue at Rs 9,335 crore, and Natco Pharma shows the fastest revenue growth with a 21.0% compound annual rate. A useful habit with specialty generics and oncology stocks is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Specialty_Generics_and_Oncology_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Specialty Generics and Oncology Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these specialty generics and oncology stocks, the main points are: Long-term complex generic shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Approval timelines.<\/strong> Launches depend on regulatory decisions that can shift.<\/li>\n<li><strong>Pricing pressure.<\/strong> Competition can reduce prices once products are widely available.<\/li>\n<li><strong>Valuation levels.<\/strong> Some of these companies trade at high earnings multiples, so growth must continue to justify them.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter specialty generics and oncology stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Specialty_Generics_and_Oncology_Stocks\"><\/span><strong>Final Thoughts on Specialty Generics and Oncology Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Specialty generics and oncology stocks reward investors who track approvals, launches and capacity use together. Natco Pharma, Emcure Pharmaceuticals and Shilpa Medicare each pursue growth in higher-value segments. Based on the 20 October 2026 close, Natco Pharma trades at Rs 800.85, Emcure Pharmaceuticals at Rs 1,766.6 and Shilpa Medicare at Rs 876.2.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track specialty generics and oncology stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_specialty_generics_and_oncology_stocks\"><\/span><strong>What are specialty generics and oncology stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Specialty generics and oncology stocks are listed pharmaceutical companies that focus on complex generics, cancer medicines and biologics, which need more scientific skill than ordinary tablets. Their earnings depend on approvals, launches and the pace of capacity use. This list looks at three of them, Natco Pharma, Emcure Pharmaceuticals and Shilpa Medicare, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_specialty_generics_and_oncology_stocks_are_covered_in_this_list\"><\/span><strong>Which specialty generics and oncology stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Natco Pharma, Emcure Pharmaceuticals and Shilpa Medicare. Based on the 20 October 2026 close, Natco Pharma traded at Rs 800.85, Emcure Pharmaceuticals at Rs 1,766.6 and Shilpa Medicare at Rs 876.2. Their return on equity ranges from 9.4% to 18.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.5% to 21.0%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_specialty_generics_and_oncology_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do specialty generics and oncology stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Specialty generics and oncology stocks have a strong roadmap in India because cancer care and biologic medicines are growing categories where fewer producers can compete and prices hold up better. The main drivers are as follows. Cancer care demand. More diagnosis and treatment lifts demand for oncology medicines. Complex products. Hard-to-make generics face fewer competitors. Branded reach. Marketing arms in India and Europe build repeat demand. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Natco_Pharma_performed_financially\"><\/span><strong>How has Natco Pharma performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P\/E of 13.7, below the industry P\/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Emcure_Pharmaceuticals_performed_financially\"><\/span><strong>How has Emcure Pharmaceuticals performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P\/E of 32.9, below the industry P\/E of 36.0. Looking ahead, it is strengthening its domestic branded portfolio in women&#8217;s health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Shilpa_Medicare_performed_financially\"><\/span><strong>How has Shilpa Medicare performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 1,160 crore in FY22 to Rs 1,549 crore in FY26, a compound annual growth rate of 7.5%. Net profit grew from Rs 60.6 crore in FY22 to Rs 243 crore in FY26, which works out to a compound annual growth rate of 41.6%. In the June 2026 quarter, revenue grew 43.0% year on year to Rs 469 crore, while net profit rose 115.1% to Rs 101 crore. The company has a return on equity of 9.4%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 17,132 crore. The stock trades at a P\/E of 57.6, above the industry P\/E of 36.0. Looking ahead, its path forward combines a growing biologics and specialty injectables pipeline with contract manufacturing for global partners. Multiple business lines give it more than one route to scale as regulatory approvals arrive.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_specialty_generics_and_oncology_stocks\"><\/span><strong>What risks should investors check before buying specialty generics and oncology stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying specialty generics and oncology stocks. Approval timelines. Launches depend on regulatory decisions that can shift. Pricing pressure. Competition can reduce prices once products are widely available. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_specialty_generics_and_oncology_stocks_investment_advice\"><\/span><strong>Is this list of specialty generics and oncology stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are specialty generics and oncology stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Specialty generics and oncology stocks are listed pharmaceutical companies that focus on complex generics, cancer medicines and biologics, which need more scientific skill than ordinary tablets. Their earnings depend on approvals, launches and the pace of capacity use. This list looks at three of them, Natco Pharma, Emcure Pharmaceuticals and Shilpa Medicare, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which specialty generics and oncology stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Natco Pharma, Emcure Pharmaceuticals and Shilpa Medicare. Based on the 20 October 2026 close, Natco Pharma traded at Rs 800.85, Emcure Pharmaceuticals at Rs 1,766.6 and Shilpa Medicare at Rs 876.2. Their return on equity ranges from 9.4% to 18.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.5% to 21.0%.\"}},{\"@type\":\"Question\",\"name\":\"Why do specialty generics and oncology stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Specialty generics and oncology stocks have a strong roadmap in India because cancer care and biologic medicines are growing categories where fewer producers can compete and prices hold up better. The main drivers are as follows. Cancer care demand. More diagnosis and treatment lifts demand for oncology medicines. Complex products. Hard-to-make generics face fewer competitors. Branded reach. Marketing arms in India and Europe build repeat demand. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Natco Pharma performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 2,044 crore in FY22 to Rs 4,376 crore in FY26, a compound annual growth rate of 21.0%. Net profit grew from Rs 170 crore in FY22 to Rs 1,372 crore in FY26, which works out to a compound annual growth rate of 68.5%. The company has a return on equity of 15.4%, a debt to equity ratio of 0.08 and a market capitalisation of Rs 15,708 crore. The stock trades at a P\/E of 13.7, below the industry P\/E of 36.0. Looking ahead, the company has a track record of developing difficult-to-make generics and has built a strong position in oncology and specialty drugs. New product launches in regulated markets and investments in research support the pipeline.\"}},{\"@type\":\"Question\",\"name\":\"How has Emcure Pharmaceuticals performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P\/E of 32.9, below the industry P\/E of 36.0. Looking ahead, it is strengthening its domestic branded portfolio in women's health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.\"}},{\"@type\":\"Question\",\"name\":\"How has Shilpa Medicare performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 1,160 crore in FY22 to Rs 1,549 crore in FY26, a compound annual growth rate of 7.5%. Net profit grew from Rs 60.6 crore in FY22 to Rs 243 crore in FY26, which works out to a compound annual growth rate of 41.6%. In the June 2026 quarter, revenue grew 43.0% year on year to Rs 469 crore, while net profit rose 115.1% to Rs 101 crore. The company has a return on equity of 9.4%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 17,132 crore. The stock trades at a P\/E of 57.6, above the industry P\/E of 36.0. Looking ahead, its path forward combines a growing biologics and specialty injectables pipeline with contract manufacturing for global partners. Multiple business lines give it more than one route to scale as regulatory approvals arrive.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying specialty generics and oncology stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying specialty generics and oncology stocks. Approval timelines. Launches depend on regulatory decisions that can shift. Pricing pressure. Competition can reduce prices once products are widely available. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of specialty generics and oncology stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Specialty Generics and Oncology Stocks with a strong future roadmap: Natco Pharma, Emcure Pharmaceuticals and Shilpa Medicare. Compare price, valuation, return on equity and revenue growth as of 20 October 2026.<\/p>\n","protected":false},"author":35,"featured_media":321235,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[3803,14185,14184,13907,14124,7424,14183],"class_list":["post-321236","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-best-stocks","tag-biologics-and-branded-generics-stocks","tag-complex-generic-shares","tag-emcure-pharmaceuticals","tag-natco-pharma","tag-shilpa-medicare","tag-specialty-generics-and-oncology-stocks"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["321235"],"rank_math_title":["Specialty Generics and Oncology Stocks to Watch"],"rank_math_description":["Compare 3 specialty generics and oncology stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 20 Oct 2026."],"rank_math_focus_keyword":["specialty generics and oncology stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/3-oncology-generics-branded-generics-and-biologics-platform-stocks-with-a-strong.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/321236","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=321236"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/321236\/revisions"}],"predecessor-version":[{"id":321237,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/321236\/revisions\/321237"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/321235"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=321236"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=321236"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=321236"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}